Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/156 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME15005002
PMID: | 15005002
LR: | 20061115
CED: | 20040309
DCO: | 20040512
Autoren: | Christgau S; Henrotin Y; Tankó LB; Rovati LC; Collette J; Bruyere O; Deroisy R; Reginster JY
Titel: | Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate.
Quelle: | Clinical and experimental rheumatology; VOL: 22 (1); p. 36-42 /2004 Jan-Feb/
PM: | Print
SU: | IM
Sprache: | English
CY: | Italy
JID: | 8308521
ISSN: | 0392-856X
CO: | CERHDP
Institution: | Nordic Bioscience A/S, Herlev, Denmark. sc@nordicbioscience.com
DT: | Clinical Trial; Journal Article
Schlagwörter
CT: | AGED; ARTHROGRAPHY; BIOLOGICAL MARKERS/urine; CARTILAGE, ARTICULAR/*metabolism; CARTILAGE, ARTICULAR/pathology; COLLAGEN/urine; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE/*therapeutic use; HUMANS; KNEE JOINT/drug effects; KNEE JOINT/physiopathology; KNEE JOINT/radiography; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE/*drug therapy; OSTEOARTHRITIS, KNEE/physiopathology; OSTEOARTHRITIS, KNEE/*urine; PEPTIDES/urine; SEVERITY OF ILLNESS INDEX
CTG: | ALTE MENSCHEN; ARTHROGRAPHIE; BIOLOGISCHE MARKER/Harn; KNORPEL, GELENK-/*Stoffwechsel; KNORPEL, GELENK-/Pathologie; KOLLAGEN/Harn; KOLLAGEN TYP I; DOPPELBLINDMETHODE; WEIBLICH; GLUCOSAMIN/*therapeutische Anwendung; MENSCH; KNIEGELENK/Arzneimittelwirkungen; KNIEGELENK/Pathophysiologie; KNIEGELENK/Röntgenuntersuchung; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE, KNIE/*Arzneimitteltherapie; OSTEOARTHROSE, KNIE/Pathophysiologie; OSTEOARTHROSE, KNIE/*Harn; PEPTIDE/Harn; SCHWEREGRADINDEX EINER KRANKHEIT
TE: | Biological Markers; Collagen Type I; Peptides; collagen type I trimeric cross-linked peptide; Glucosamine/3416-24-8; Collagen/9007-34-5
CR: | 3416-24-8; 9007-34-5
AB: | OBJECTIVE: Glucosamine sulphate has been shown in a large double-blind, placebo-controlled clinical trial to prevent structural damage and improve clinical symptoms of osteoarthritis (OA). We investigated whether early response in a newly developed biochemical marker of collagen type II degradation (CTX-II, CartiLaps ELISA) could reflect the long-term preservation of hyaline cartilage. METHODS: Study subjects comprised 212 knee OA patients participating in a clinical trial of the effects of glucosamine sulphate. Disease symptoms were assessed quarterly by WOMAC scoring and X-ray analysis was performed at baseline and after 3 years. Urine samples were obtained at baseline and after 1, 2 and 3 years for measurement in the CartiLaps assay. The measurements were corrected for creatinine. RESULTS: At baseline the patients had an average concentration of urinary CTX-II of 222.4 +/- 159.5 ng/mmol creatinine. This was significantly above the CTX-II levels measured in urine samples from 415 healthy controls (169.1 +/- 92.3 ng/mmol, p < 0.0001). There was no significant difference in the CTX-II response in the placebo group and the glucosamine treated group. However, those with high cartilage turnover presented a significant decrease in CTX-II after 12-month glucosamine treatment. Thus, three group with CTX II concentrations above normal average + 1SD decreased 15.5% after 12-month therapy. The 12 months change in CTX-II in OA patients with elevated CTX-II at baseline correlated with the change in average joint space width observed after 36 months (R = 0.43, p < 0.05). Increased baseline levels of CTX-II were associated with a worsening of the WOMAC index (p < 0.01). CONCLUSION: The data indicate that measurement of urinary collagen type II C-telopeptide fragments enables the identification of OA patients with high cartilage turnover who at the same time are most responsive to therapy with structure modifying drugs.

» Volltext »
» Fenster schließen »